<SEC-DOCUMENT>0001193125-14-313413.txt : 20140818
<SEC-HEADER>0001193125-14-313413.hdr.sgml : 20140818
<ACCEPTANCE-DATETIME>20140818165936
ACCESSION NUMBER:		0001193125-14-313413
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20140818
DATE AS OF CHANGE:		20140818

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-187508
		FILM NUMBER:		141049760

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d776001d424b4.htm
<DESCRIPTION>424(B)(4)
<TEXT>
<HTML><HEAD>
<TITLE>424(b)(4)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement No. 22</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated May&nbsp;30, 2013)</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed pursuant to Rule 424 (b)(4)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration No. 333-187508</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>125,000 Shares of Series A Convertible Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>12,500,000 Shares of Common Stock Underlying the Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to Purchase up to 6,250,000 Shares of Common Stock and </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6,250,000 Shares of Common Stock Underlying the Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g776001g38y53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement supplements the prospectus dated May&nbsp;30, 2013 (the &#147;Prospectus&#148;), as supplemented by that certain
Prospectus Supplement No.&nbsp;1 dated July&nbsp;17, 2013 (&#147;Supplement No.&nbsp;1&#148;), by that certain Prospectus Supplement No.&nbsp;2 dated July&nbsp;19, 2013 (&#147;Supplement No.&nbsp;2&#148;), by that certain Prospectus Supplement
No.&nbsp;3 dated July&nbsp;24, 2013 (&#147;Supplement No.&nbsp;3&#148;), by that certain Prospectus Supplement No.&nbsp;4 dated July&nbsp;30, 2013 (&#147;Supplement No.&nbsp;4&#148;), by that certain Prospectus Supplement No.&nbsp;5 dated
August&nbsp;6, 2013 (&#147;Supplement No.&nbsp;5&#148;), by that certain Prospectus Supplement No.&nbsp;6 dated September&nbsp;4, 2013 (&#147;Supplement No.&nbsp;6&#148;), by that certain Prospectus Supplement No.&nbsp;7 dated September&nbsp;23,
2013 (&#147;Supplement No.&nbsp;7&#148;), by that certain Prospectus Supplement No.&nbsp;8 dated October&nbsp;29, 2013 (&#147;Supplement No.&nbsp;8&#148;), by that certain Prospectus Supplement No.&nbsp;9 dated November&nbsp;6, 2013
(&#147;Supplement No.&nbsp;9&#148;), by that certain Prospectus Supplement No.&nbsp;10 dated November&nbsp;13, 2013 (&#147;Supplement No.&nbsp;10&#148;), by that certain Prospectus Supplement No.&nbsp;11 dated November&nbsp;21, 2013
(&#147;Supplement No.&nbsp;11&#148;), by that certain Prospectus Supplement No.&nbsp;12 dated December&nbsp;5, 2013 (&#147;Supplement No.&nbsp;12&#148;), by that certain Prospectus Supplement No.&nbsp;13 dated January&nbsp;8, 2014 (&#147;Supplement
No.&nbsp;13&#148;), by that certain Prospectus Supplement No.&nbsp;14 dated February&nbsp;10, 2014 (&#147;Supplement No.&nbsp;14&#148;), by that certain Prospectus Supplement No.&nbsp;15 dated February&nbsp;12, 2014 (&#147;Supplement
No.&nbsp;15&#148;), by that certain Prospectus Supplement No.&nbsp;16 dated February&nbsp;18, 2014 (&#147;Supplement No.&nbsp;16&#148;), by that certain Prospectus Supplement No.&nbsp;17 dated March&nbsp;3, 2014 (&#147;Supplement No.&nbsp;17&#148;),
by that certain Prospectus Supplement No.&nbsp;18 dated March&nbsp;20, 2014 (&#147;Supplement No.&nbsp;18&#148;), by that certain Prospectus Supplement No.&nbsp;19 dated May&nbsp;13, 2014 (&#147;Supplement No.&nbsp;19&#148;), by that certain
Prospectus Supplement No.&nbsp;20 dated June&nbsp;9, 2014 (&#147;Supplement No.&nbsp;20&#148;), and by that certain Prospectus Supplement No.&nbsp;21 dated August&nbsp;13, 2014 (&#147;Supplement No.&nbsp;21&#148;, and together with Supplement
No.&nbsp;1, Supplement No.&nbsp;2, Supplement No.&nbsp;3, Supplement No.&nbsp;4, Supplement No.&nbsp;5, Supplement No.&nbsp;6, Supplement No.&nbsp;7, Supplement No.&nbsp;8, Supplement No.&nbsp;9, Supplement No.&nbsp;10, Supplement No.&nbsp;11,
Supplement No.&nbsp;12, Supplement No.&nbsp;13, Supplement No.&nbsp;14, Supplement No.&nbsp;15, Supplement No.&nbsp;16, Supplement No.&nbsp;17, Supplement No.&nbsp;18, Supplement No.&nbsp;19, and Supplement No.&nbsp;20, the &#147;Supplements&#148;),
which form a part of our Registration Statement on Form S-1 (Registration No.&nbsp;333-187508). This prospectus supplement is being filed to update and supplement the information in the Prospectus and the Supplements with the information contained
in our current report on Form 8-K, filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on August&nbsp;18, 2014 (the &#147;Current Report&#148;). Accordingly, we have attached the Current Report to this prospectus
supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus, the Supplements and this prospectus supplement relate to the offer and sale of up to 125,000 shares of Series
A Convertible Preferred Stock (&#147;Preferred Stock&#148;) which are convertible into 12,500,000 shares of Common Stock, warrants to purchase up to 6,250,000 shares of our Common Stock and 6,250,000 shares of Common Stock underlying the warrants.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement should be read in conjunction with the Prospectus and the Supplements. This prospectus supplement updates and
supplements the information in the Prospectus and the Supplements. If there is any inconsistency between the information in the Prospectus, the Supplements and this prospectus supplement, you should rely on the information in this prospectus
supplement. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Global Market under the trading symbol &#147;ABIO.&#148;
On August&nbsp;18, 2014, the last reported sale price of our common stock was $1.39 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Investing in our securities involves a
high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;Risk Factors&#148; beginning on page 5 of the Prospectus and beginning on page 20 of our quarterly report on Form 10-Q for the period
ended June&nbsp;30, 2014 before you decide whether to invest in shares of our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is August&nbsp;18, 2014 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): August&nbsp;18, 2014 (August 18, 2014) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8 &#151; Other Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;18, 2014,
ARCA biopharma, Inc. (&#147;ARCA&#148;) announced that the Company&#146;s Clinical Trial Application for Gencaro&#153; a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation, has been accepted by Health
Canada. ARCA anticipates that clinical trial sites in Canada will be active in the fourth quarter of 2014. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces Health Canada Acceptance of GENETIC-AF Clinical Trial Application&#148; dated August 18, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: August&nbsp;18, 2014 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Patrick M. Wheeler</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name:&nbsp;&nbsp;Patrick M. Wheeler</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title:&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD WIDTH="86%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:55.75pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit&nbsp;Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces Health Canada Acceptance of GENETIC-AF Clinical Trial Application&#148; dated August 18, 2014.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g775971g31o59.gif" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA ANNOUNCES HEALTH CANADA ACCEPTANCE OF GENETIC-AF CLINICAL TRIAL APPLICATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Canadian Site Activation for Phase 2B/3 Clinical Trial to Begin in 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO, August&nbsp;18, 2014</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies
for cardiovascular diseases, today announced that the Company&#146;s Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> as a potential treatment for atrial
fibrillation (AF) has been accepted by Health Canada. ARCA anticipates that clinical trial sites in Canada will be active in the fourth quarter of 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA is evaluating Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for AF in the Phase 2B/3 GENETIC-AF
clinical trial, which is currently enrolling patients in the United States. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically-targeted
therapy for the prevention of atrial fibrillation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Michael&nbsp;R. Bristow, Founder and CEO of ARCA, commented, &#147;At ARCA, we believe a
personalized medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of each patient, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. If the GENETIC-AF
trial successfully confirms the atrial fibrillation data analysis from a prior Phase 3 clinical trial, Gencaro has the potential to be the first genetically targeted treatment for the prevention of this important cardiovascular disorder and provide
a much needed treatment option for patients in an area of high unmet medical need.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Atrial Fibrillation (AF) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Atrial fibrillation, the most common sustained cardiac arrhythmia, is considered an epidemic cardiovascular disease and a major public health burden. The
estimated number of individuals with AF globally in 2010 was 33.5 million. According to the 2014 American Heart Association report on Heart Disease and Stroke Statistics, the estimated number of individuals with AF in the U.S. in 2010 ranged from
2.7&nbsp;million to 6.1&nbsp;million people. Hospitalization rates for AF increased by 23% among US adults from 2000 to 2010 and hospitalizations account for the majority of the economic cost burden associated with AF. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AF is a disorder in which the normally regular and coordinated contraction pattern of the heart&#146;s two small
upper chambers (the atria) becomes irregular and uncoordinated. The irregular contraction pattern associated with AF causes blood to pool in the atria, predisposing the formation of clots potentially resulting in stroke. AF increases the risk of
mortality and morbidity due to stroke, congestive heart failure and impaired quality of life. The approved therapies for the treatment or prevention AF have certain disadvantages in patients with heart failure and/or reduced left ventricular
ejection fraction (HFREF) patients. These include toxic or cardiovascular adverse effects, and most of the approved drugs for AF are contra indicated or have warnings in their prescribing information for such patients. We believe there is an unmet
medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in HFREF patients. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GENETIC-AF Clinical Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GENETIC-AF is a Phase 2B/3,
multi-center, randomized, double-blind clinical trial comparing the safety and efficacy of Gencaro to Toprol-XL for prevention of symptomatic AF/atrial flutter in HFREF patients. ARCA plans to enroll only patients with the genetic variant of the
beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company initiated the trial as a Phase 2B trial in approximately 200 patients. The GENETIC-AF Data Safety
Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend, based on a comparison to our pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and seek to enroll an additional 420
patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The AF indication for Gencaro was chosen based on clinical data from the previously conducted Phase 3 heart failure trial of 2,708 patients
(the BEST trial). The Company believes data from the BEST trial indicate that Gencaro may have a genetically regulated effect in reducing or preventing AF, whereas the Company believes the therapeutic benefit of Toprol-XL does not appear to be
enhanced in patients with this genotype. A retrospective analysis of data from the BEST trial shows that the entire cohort of patients in the BEST trial treated with Gencaro had a 41% reduction in the risk of new onset AF (time-to-event) compared to
placebo (p = 0.0004). In the BEST DNA substudy, patients with the beta-1 389 arginine homozygous genotype experienced a 74% (p = 0.0003) reduction in risk of AF when receiving Gencaro, based on the same analysis. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA biopharma is dedicated to
developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically
unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first
genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF trial. For more information please visit <U>www.arcabiopharma.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company&#146;s capital to support its operations, the potential for genetic
variations to predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, and the potential for Gencaro to be the first genetically-targeted
atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking
statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether they will be sufficient to meet the Company&#146;s business objectives and
operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s intellectual property; risks related to the drug discovery and the regulatory
approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s filings with the SEC, including without limitation the Company&#146;s annual
report on Form 10-K for the year ended December&nbsp;31, 2013, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contact:</B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g775971g31o59.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g775971g31o59.gif
M1TE&.#=AO`!&`.<``/____?W]__W]^_O[[6EI;6MK?_W]\:UM;6MI>_GY][.
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M<]:E0MZM&-ZE&,ZM*=:E*2P`````O`!&```(_@`!"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRI3)`@`2
M6Z.B3)G2Q(D3)D#;-!'BA`L3)4"5./G7Y(>I6B8("D!B48#5F10%5/W((H")
M'7)\[&S2YF?0H46/)O7)Y,>C5#A.#)Q:]2I6B5HKYNUX0DL6+/Z:"&[RQ.R3
M)T*Z"#G\!"B7GTJ;)')F1)56%GOQ-M":^2X``0%"BS;0N7/#`%9-7SS!:I\2
M?DJ0(A7RQ8OM-T^2B'EB6X@0+UQB*^FG2$D3(CH$L*A)4<(*#:H1#D@PH/J`
M!MBK8QB`(<'V`10"_E`,,/T"@PT%TA?8P.'!A034*4SDD.%CK2;XD";E\D0*
M(S%?B"&@.U<`&&`4<_#'1"7XY,?$%,Q4`0!S$]613PH0G:%/(!RFH88\:*0A
M8B!_E!@(&BAPX(!X#Y'WP"%_X-$')7[4X0<A>-RA(QZ$_#&(1`/@\4=J&NF@
M`QGW*`*48XB)T<4K87011AC?@!%E%%<LLIMO2S+1$Q9E($%A1!?P<<<>\CGD
MP`<;K)&CCG?P@8<@"ZRW`!IX3&+F&0DT)(`#'N3!!Q]_+``!!JE1X``'>L!Y
MQQ^?012"GA%$-Y$TTF!15D_\-=F%#Y?<(L<5CVBR22:DG@)+%W,DYEMA_CXU
M84\Q%7DP21]W0#!1`3I.<\<D*'2V`2`YIG.(`0I9E4`@>DZ2A@8%[46!!7P`
M0JRE".DQJ`?81N2&&ST)UL837XPQAAAA7%$/*')@`H8.M6""BBFE,#-E%T#\
M(`91/CU!QB?=)F2'CGPL@%<`>\1I)@C1"K"`KW&28.F?@9AY!QH)8!L`M3JF
MZ=`%L@Q:1\`/S3,/$TY,P007B3TRY160&)$,#_1L<@0V<B#3BSI%9))$%%$D
M,<9B^F%1#U4226#F)'<0XC%$:9A9K6D&!+!&G'T`TB="$>S!]"1K4(#L0@&D
MP`T?$3PT0!U2WW$!R0U54DED_0D1!1BKW`(&_B:.J+(+,E0(L`THTJBR@Q'S
MCG))%$'4!I0336`"=T%HA$QP?1+5$><=>+`8K09OWE$`0A@DK&,!%,`=`!W<
M?/!0!9/@(36&&OGDA!*'">&D&U1@P\,JJVQS0BV[`.!+.]L4PPLHHY0ACBE1
M=`'@$X]A\<I$&MQA01Z;KS'Y0&G`V<?8!@E`B(Z3R!,M`!2H0?`@WP,P@!T>
M."2`'7P,&^<>#6BT9.[H"L,C7&$,56BA'3A`0@U$@011#`,)PXA'.32A"EY@
M(@P_^\$3VJ`$ZTTD!7P`00&XH2-`]"\BX=/1^!+R!S@5(EH&&`33.+>UB(3`
M=0V!@+,,D$(^T`XC_FQY@AC&``0?7"%+I!#%$;9Q`R0<014V4(4H!%`#>%CC
M9G+(Q#&N`+3=/,&#$B&$'0!0ICA-X@$22>$=5HB0\]UA&F@PR`5\9:8UD(0.
M?&````HPPSL,(".Q88(0@)"$2_"`&>Q`!BAP<`0D5,$6[9!&+6IA!>&=0`"^
M<(0<Y&`*,+CC'5'`31.N1Z9)6```!@@$^GZ$0O&1KR`4H`3!#"85&:*O!2,Q
MP![^@"P'P"D6'``D[H3P@R'TH!GKH$89M/`+&U@C%;!8!17&H0D=:.(&)SC!
M+K1@!1Q0(Q1@B`(0%M.$8\0/CQ<0R`7@U+E6JO"5!&$`('0D"X9))70F_AQ)
M"R:Q@8'XP8QUR$B_A/`&(%Q!5,U012./X(@P+$(:ZJ"&+TX@"E7@0!67K((5
MM`$)EXWA,.7\'LCJ0#XT;"X$[EPC/`4R`&8!8A(H+<@%]*2C0,0O(@*H0SX%
M0@*F#2J=%VG#N)[PACF$X17G6$0M;G`$=`PA":/H'0X8>(1B[&(7!O"%%D`!
M!E2@(@QB$*4Y'T*!/'`CI@+9IXX""C5VFB8`@TC''0!1`=-LP&)W\)Y((L`'
M.PX$`W#B`PHP(E3^O*$+2>@$.7+1"RM\(@MC>`0K2E')*APA$CJP0CE$H0-;
M4`$,G4B";D`Z5H>$(!:R2-U`*!`Z<[15A9X#_@`&'E"'20"B$!=8*0!2,$,^
M(&`D:YB$KO(B@$(HS!`8B<T;PH`*4#1"!U6XI`!4X8DGW`(2IQ@'.'`PC&%\
MDQ<F((T31:&)4D""$5\0PBLFISD]=,:D-=4M0E(HB4?500^%P`6N^)`&!<2V
M((-P5`%N2E8\X,$@'>###--FD=@DY@JPV(06;,'=*JC"&V^(`BH6\8U0@",<
MU!!'*%9A`PMOPPI:V,$H"O2$9QS#(09(0([Z69`.]!&H#5'CH^P0LAD"`@+8
MHL/F1">2#$Q"$'*$TR1&UV"D2*$+5T`%)/!6BVX4HPC/0"PF+B')4(2""J>0
MPS*VH05I(`,2J+A"_A?$"C=>30(-:SC$(>A`AS4T2H6LS#$[,4"!"Q0@=&DX
M(4*H93%:?D0`)JW#G.DLB#H[:DA-)JJ32`4)4&#C!$BP03:>T`53H$(;FP`%
M\'A0"TQOHQ9R>$42I(>;*926;'\`A"`63><SG($.W-,1FARBQG:&Y@&.2@,&
M$E(!O/KU(QS@W"#H3.=E#R(-)-21`BPBU'$5]!8\H`(UJJ&#&U2A%L\(`A".
MB@EY]4`7UKB&"891#5K`PA0^^.@30MH0!DQ"#Q1H``7V'9X`T(`#?<0A0WKM
M.0&L0$]F0C)"RJ@C2'ND=)-80+]%@QT'&`).A["(3\8UABL@HQG-"'4<_FQ1
MA2I0P1G/^,$;H`&$6U!!H='8P29X(8UF@`(30"`MR<(73(0T('0OU/.."I(`
M/]AV&H"@L4$"@`=`6,P!'UE`M:"%$#[NZ+\0"61B7G$+48$!&9?0!!).H(-D
MX%P9RLC$RY<A@!/,8A7(8$8/>C"J-WCIU0D!`><&8"GX9NV/`V>G06"WQD<!
MWB""4++2.5(QAQ\$8>A#(T6T[J0N1.&HINB%*'SQ"V`(0!3!$,8-='"$81`#
M!\4P!BL@<8PP`.'U1&E"&`(6`C[85"$;"*SD%])#68P)``WXPZ`&U0&$J/57
M<:0(".HG1T#$XH<(N=H=)'&&B@S&$I+&4A)R_J&)6NC"$;L0`")L`(`J[(*B
MO)"F#GK1@RN`]0O4<P(6PB#?@02@MHL_2`)P%2>%\YY@OA<M\D0PAH!C!($!
M(C`H<R4!%'$&;%409U`M4*<0#``GAF!/$A$;3L`&XQ($78!8LS`*4Y8*JJ`#
MH$`+`@`OMA`).W`*D!!5H'`+YB($CH$%<D`5EI(!<G)X">$^.X(H_Q<GLH!U
M<-5'N/`T`S$`\"4):<"##B$#LB`"!H$!LL,M"T$!>R`UU3<10-$312$%=@,)
MII`$44:".[`*H(`$5C`*K*`)K>`*J/`*CP`&5[`3EI`4B0`+2(,0`B`(?=40
M+1`+"L-\"A$^@])._@8!`H6`5[]U$`[P!S,4"`:X$`(@`6R#5@-1`'Q@!TZ(
M$+;$![+`@!+A`S[0$[@C1%%`BHP0-*`0"CP`"8X@"EH@!Z-`"J5@"E?`")8W
M!V_P!I9P.TJ0"*=@*0:P`//4<PO1`(0@-7M`=7SX3W""A`,!`IJC0FAD&A``
MB36%.62S`2W$!Q,X$`F0A7FV$#J(/FF`=0S!`SR`!8I0"4R`?6]`4&(0!6YP
M"9C@,W)@*C[3`YS0"5$`!T$@!>0B!(*!%)[P"0K!`;(D"<BH$`;00CHB"8<@
MC>(8.G?`C0;Q`8Y2!QFP4@+P`/C#-'\PB>6S`0;&.4BX`/5U;`L1`>(C_CI7
M81<+@0B(D`C%@3)#12Y=X`:+,"6,<`6-T%`"!`F0\(%!L!B((1A`4021X',?
M\`>24%]H`!V6T@`MX"AK9`$/4$,L!0&#@%=WD`8,X)7V5S$$\P<I(`&")A`!
M\`&:PS2!T`)M21`.L`"F<P>!8'\@@)(Z8@<?@($'(0`)('6.0@D%X`*D03(E
MUP-L@!1.4&V'$01ND`1OX"1P$`=R,`=.$C2*<1A+,AA9D$`&,0!T4`<#PTYY
MH`=Z8)(?H`=UD(4JM"-VX`=Z`'4>`)NQ5BVS^0>!H`=T\%\/X'1Q0BQ_4`>"
MP(,!<`$A,`@)LP=I,`@%P``/<!X+L`:!D",\_O('@P4`*%`(?Y"7=V`(]R5P
M`W$!^%4'.3)/<\4Y@5`(<O80..`#6'`4ML,?KN(%Y!($5O(%`9(88\`%1M&%
M@D$&8?)X'=`!(=`"#,``)1`"">H!G2@!Z[$!%<`!#<H`+5`!"6H&?_0!'M`!
M%MH")5`"#LH!')J@2U<!%OH!&LJA!4"$&"`!&W`&(2(B(J(&<"8"!=`"&7`!
M[R$0*I"@&'JB"=H!)CD`(;H![-&@U<D!&]`!!5`!%?`0:M@#4W`[7B(8B,$8
M0@`%5S!.!(D8!AE(3O!%6:`%1R`0;Q4:J0$:`;!O;Z5O8K.85B$:+(*G`6"G
M=QH`6]")`"`:G&$`_ON6$*$!`@X0`1(``1F0`1)P`0[`9VVZIZE1-:)Q$`,0
MIV*S%Y;:;PVQ'#:!`TF@!$NPI8)QIHP!!5&P&%*@'TV@,O;I!$!`!1*R'*;Q
M>W@!$<35$NK($J'!ICJP`SS0`S[P`\;Z`_F"K$%`BK!WK,8Z!$10!$;`2)-#
MDYYQK7Q1`S9P`]S:K=[ZK=V*`SAP`S:0`Y>$K>@:$S<%JNG:KN[*AP3&IA3`
M8"NQG(+YKOC*AQ'P`!R`2PDQ``]PKQD1`!#``4B:KPB;$!>P``N@D08A`2B`
MB1H1``S`L&:9L!BK`0BP`!=+$"#0`;O'$1FP`!M0?QC[KB-+`B8;`"#0_JL*
M,0`2X+(`P`$+8)(GFZ\"L`$-"Q(?T`$N:P`$L`$T<+,WJP$+<``#``*0:A"*
M<@%U^1D:X``.\+2!6B<2(`$.L%)W61\#`*14ZY8-D``/X(0:<`$N(#\S$(YN
M":1_E`!`:A4SJK8&@1T7D`$"B[$"4`($<`$2$`,DD']]=@`(,(D4``$?X``,
MP`'#-A<#,+(,(`,50`(F.0($X``SD`&4Z[`"T0!`Z@(O4`"']R<EL!X)P``B
MZCE=BQX0<`$04``D@`$:T+HD8)$!X``NT+H+<+<)VP`(0`+4*0$'L`#D$Y(.
M4``K8(`"``$U2T86H)$@0*$+@`'+N0+Y9P"]_OL`A^L"U,NT#Y`!">``*]`"
M>Y$`&<``%C"=YO$!+$*\))`"''`H&TN="4`"$C>W/XH!YLL!\8H5$;`"OOM'
M)2"\JP4!&D``"!!;&+`>6G$!%H")2IL>6@$#=5(0&."_90E\VRL5&3"V``"^
M]`H`(``")9`"!?``!E`=J^6]"-#`?,:P%>``%(``&]`9`]"@J=,"'$NT!$&S
M#`!X%DH0`=``+\"5!?$`RPL`#Y`"^;>U+#7!!`$!U`MX%:Q'<R$!#]`_!L`!
MJ`/$O$NRG1C$%>L!;Z.\&^```J``"_#!P/<!&="V"."O.@Q\)'M"`W#$`W&7
M&]"6O!NCG[$!%D#%_FQ:L8OK''#<QP@0CN"KMA>P`7]D`!>P`IK;OVF,$`E0
M``OP``)``99LQA1``A7P-`+``!^`+%F<PW$,`!FP`BZ@%6\IO@1A``=0`!KP
M-`M+Q859`()9R306`!WP'`11QR6P%PQP`.3#R_6QG`5``'Q6$#3[`+U:L270
M/\Z1`5:AO"[P-!K@`7UB`,K+`>%QRAN``*11N"JPN'=,`!E0M@3QR.F4Q07P
M-@+!`@90L9@C`0M0`J_D'-`A'@%``L[8P;F[G#I;`AK@E0TPI18I6PO``?VC
MR1N0.AI`NFK;`@5@``U0O`O@`A%@SD2[`"1P`HC[`9U(LQO\SY6<-A'@_`$2
MD!D8P+!0-P`%P-`%@1Y_8K>-FAE&S`"-:LDZ3<LH8+,"8<14=P$ID#:E_+XU
ME+,%H``Z;<EU*[/XBAX9@*$=VP$>$)@;^0`:<$.=(0$\:K?86Y>\C$8C$-,,
M,+RHC`#3B0$;&P+_C,0^FQ!,BBP"H,7\7``>4,9S(0`5X-$E8`+I40)0C:^(
M^P`K@A`0P,&EJ:@3@(1\_<<1X+5+)P%_A+A..X4/``$-8`"-"ATR!=2?L;3J
M!%0&8,5R*P`1P``7(!^,"J@W:[(5T0!UTK&Y>LJVS1!H?-:WO=LB(0""2]N\
;'=SCH14#0``5+=S(G=S*O=S,W=S.S1`!`0`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g776001g38y53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g776001g38y53.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("
M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@,"
M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`__$`#<```$$`P$!```````````````%!@<(`0($`PD!`0$``P$!
M`0$````````````!`@4&!`<#"/_"`!$(`&4!&`,!$0`"$0$#$0'_V@`,`P$`
M`A`#$````;_````````````````````````V>?\`7%OR_HM/+^GM^N&GY9>>
M5>O=:.0^[U7IF#4;HOGH>8U#L$R%>EPW-3E(X7C1UCO/6-:;HX#U``*Y?SWV
M^?!5_HO$I[/R\GE_9"YWW(&N]<_??N*<.\\A7F4-BX%/8"-8H#5^B$A52T<L
M56U\DM$=B5!MNU"E6A1*2V=K],@!6O\`FOO'5TNL=_=ZGW8>_MC8XW8,CB=S
M+GV?E79T_A*8J5KM5<5N#9/%?FG7TNB+TJQ;>L^<LGT/M6D%1I.E>^F85HKK
MQ6\KW`"N?\W]P]>[TVTP4_=@I[ORI^L_>/OFV^E/[#S3KZ?P:65<EF:J*GT@
M3K7G/F<EKV4;):.1+MI8GT578#`&I5^)EJB4?1ZNX`*V_P`T]T[^TU;FZ;6M
M?F-JY>BUG%X/U8O`;R6?LO+.KJ?"DE;*FF2KA/\`4R2^5?-0^BLGSV6^]=I\
M\3Z4I[J&HFFI6@FF2L5LZ$VILH5I_G#NU3/\7'U6M6=MXDSQ>A#YO9-C0;"<
MONW%N/IO'58G\=9$%5FQE\JYY?FG;],9(:R5JQ7TJLB>2VM-T@)7&1R3;(\+
M8J*IR7[M[@(_X;9Q3\GZCWRPZ+CYX7CP_1T]GJ9E^N<VV?TD>#@LDM8?3C9+
MZ)\<2=ULNQ#*;K,1&U-4Z)<S%]9&'*O5)Z1#+P4J)+ZAYXO/!K,LUK9F/7/'
M9=::=.N-:2Q:,FADRC05V1O60"`*P!D(Q60,@!B,T&``#S(D)!.>E.$Y.Y4N
M$/)(,12/6EZ&U:N2(1T`<1N.@XQ*5RIZ@`````&@UQLPY::H_P"&-;V)P`/=
M&HNY[V($LGQ%UDJQ%UOB=`^AEHX1X2YH`````#40$\5<4C35STT1VQ%U/Z,6
M<#)SS%IVD.&M84+&\I'+2C"".NE`R``````!@`"0M#E/([T%`,05F"@(*`,&
M3(``_\0`+A```@("`0($`PD!`0```````P0"!0$&`!`1$A,4%0<@(187,#$R
M-#9`02)0_]H`"`$!``$%`O\`Q'[(2$"7=A.7NEGGF+&TY[E:8YBVLL<0N\&E
M\CMHG7SQGIGGOU1$ON]9R6Q4D)`LD&L]^I3#!$^Y:\MD6\ZZ3*^PTS.>_3/'
MK1.NY'/?Y7329;$'Q\`#QY$KC,/(["F#Z3QX<UI9%4Z9YNUK-ZZU^PC9U/2R
MU>C?@-.&;%?4=>7#MVJ+5BVC;0RX3\N;-LZ^O@J*JXW,Z6O4J`V:.H;ALNIQ
MU]M:?F+\SS?+/+MSK=GBVJ?DQ'&2@7S+G:$80/@F9#&3C`2DXQ&..4WT1Z;'
M:8J:A[7IXT[X;67;..A/T#_D'^;D2`]>T)8Q[U@L0`8.QL-VDF)%3MT=2#8*
MKA@L'\N;!98J:DFOSSIGPWL\0)CY(Q[D6B+'+0G_`$J;$,3/')6\1G)J,.4_
M['F>;4Z&ROC6-$91!GV2]&2)1\)^COF%V[NKE9&##WQ`<J:=&E6VC.84.G0A
M*_Z]NNWNC>NRV5&155CV.\"6!Q]8]O-7**'#A]:#"CX<K+Y'ED\>,_E3?L>_
M'6QHJ:C3ANY?9:AYOM*O6,Z1:^XTW?A/T#_D#Z(+),P7M6NJ>U!<(6BOK*ZK
M/*JN8$Q.'3OQ=U9OC;4$U=2JP7YL:M01YOE("M9T2S]=3=^IHY$<!L1X!CN0
M;.<PFQY@2L>/!)<J8Y&ESXA7@9!HPA5JN;LF!NCTJ]#3V`RC)!DX@`&<7O(C
M",/=*#W='4[_`#1OKMK-#W742G)I^WB%",HSQ^7-LV]2L7TM+T='\0+X/IM?
M673I^_-R5"W0Z9>"J+,11ECTM:OU/)@9%S$RXC$A<8\9>=BRS7TYSDC'$<6M
M9[F+&@47*W6!5;'&M.6>+GX?:_VK-8#4L.:>N^;[O]>Q%+4%J\_;ZL:)2,N!
MTM%0F,=L6FHTEKD6I6"/):O:,X#H%"/#M,-I/[`46>5VK!K&.W&M/6>+]WVO
M>%'405Y>G;F8QSSRX<\N'/+'SRX?(S:1`QCA"8%!)T+X^G^]#VL`M_V,_3D&
M1SLDW1NB=L%U!K^5Y)WQB(JT)L=F[%1:OL_+CP1QEMDK$+LN^,89M5EQC+XP
M^[K>>G8B=DW8@3P>X6!PMNN&?","%E2Q&X;\2V:]*DN$=4A5JR55>\#+YB>2
MK4^%9'7Q3PO:1PW:6F/56;Y\*ITJ>%UJ<?F&.7+;A"">>GB&1U:_K'L0A'-A
M#U[S`HO-X\IQ]UK"BY#>@6IE\+K?B/HP>$O70%G@*@(6)1C*.*8?/^!0KER/
MG52&KQU*#PS5N"GA",(RJ!Y<6IUURG%YP5E1JASCZ*UXE.*UP5!I5(4^/)0?
M"6D"08`#!'^D4`S075`J/\7M\H#_Q``[$``!`@,%!`@#!@<!```````!`!$"
M(3$#!!!!41)A@:$%$R`B,G&1P4)2L14C,#1`\!1#4%.BX?'1_]H`"`$#``$_
M`?Z)=+I'>H]F&@5AT5=8`(;>S>+5?9MQ'\I'H^X?VV7V;<'\'!?9ERRLGT5[
MZ/-W/=FZ8_@;M<*<%EV6X(`^2]NQ]>U<KM#=+.`LY,+^2O-O*G<.8R5K;[`A
MBA/=%?)1WIXK-HI$H6QZU@9"JAO`!&?U1$%K91$U-![J^0""\6D,,H53&FR?
M"11;\>2ST99O0K)O1!L!Z)SY)MRD>"W9%;J8\%3LDCJH0)#95M;]7W8@V0T9
M$QQF*QLR3"9^2BL39PAXFCAHH;2.S!S,52KK;V<$,G,9^JL#$("3,C)=)_FX
MA0+=IA-?Y-1,3,^FBKPQ\ZC/"11KO9<@F>M!,`>Z?AA)4PY+R4RX>JG31:/V
M(C%U4.S5E>3:B1@[IU71]EM11[0:,&@T5Y@[VJZHBS.U178QP>&SD5=3:?%"
MRZ2_-1Y8NS!YE`$4DRI/X53'P@AC,IFS59:9_P#BD*)E,!OAU[>1%$%/R'9A
M?JX0V2O%C:1`N=@<U8VT5VM28`8X1XBA>;E;PB,Q;!%1KN5YM8;8GJ1]W#XB
MKI9VA#P1]S(%7<1"$BA&:Z1#7F):8;DV^B`X#1<F7+#.M,']/I@$,]WIA[8\
M,=E^"R:J8BM>Q=HX+:"'JIG9F%>+$F'0!6MBT&Q!#L[>:CNPABLH81)07:*"
MT[OAC"L+$V9>D!^'>@-F#;(:$+I&,17J)L\`^29LZ8@Z98-PW)FJP^JY+312
MGDJ;E_Q4I)ENHO9<@LUX6_;*DJX-P0`R?CV+A??X>/9,30J"^7:U&TXF.:^X
M,S&-&=&&PCV>_"-FDT]A\T,J30M+%B>L!;]R5_Z2L]CJK.)V]$2_>.:=E[8R
M]$^>:Y*A<57G-DY&<E1,-%YSP!P=4WNN3363:JDAAKO4UQQ$D\0\,9"V[3YC
M);=I\YDMN/YBMN/YRJ;^UR[0G)/^H^JJVS-45"!JIJ?IA)]&5#297):39;AE
M7"<EY+=FI4YKS5#]$6'^EDLER;\2B`=4H&9<F3K3<MP6Z@PHVIY8<75%IFF7
MLJU7LM4!+RS6;SE^V0K.2\E2GXO);@J)UR3\,)^0%%R7)`MN9<EF]),MRX*B
MIAR5)+7)2>GZ2F/M^%[=L/_$`$$0``$!!@,%!0,'#`,```````$``@,$$2$Q
M!1!!!A)187$3((&AP2(RT105,%)BD;$6(R0E,T!"4%."X?`T1'+_V@`(`0(`
M`3\!_DF/8_"X&X#;WVGC?NCXJ+VSQ=^WOPD3V+'U?@ORKVD'_=H;40VEVD:!
M(CC[*_*C::=(V0'%,;6[0AH;T;07X26`;:PN)O68!\R1$"[6A4Y4[E!W):*7
MDK=Z7EGPSF!=>G=Q^/>8H_;;?D[K!MH$[A&(YR&'+6Z78GPLL+PD/W4FB1N<
M1KPGS4)@X:AHAX1(NP9`C4(83OP+;XL:HP>XP]>_PL6"8+$(^=14,2R]F/!;
M/Q3V,PMP^?#VY:W7EEY(T%!;N24JW\%Y93'265>JJ>F7712U4O'+T7(#Q[S8
M#40^FU_'X+#<.F&6V),M<.ED(5T(1R_?M"&;8;%+!J7$)UBHB7[YR[A0VX:H
MUN\$\=0Q=M.W=&&1^SY_Y4?A<2UOO6F0XAOJ*/@W+EEK<:_PMCVB=GX(FIEF
M.>BL"A;F%*7CF)!H:+Q0$E+Q5NJUIXKR'#+RRITSK9"R_#N=F&HE[-KW7FFJ
MPAF$8`#R(#!,C+426U[UZ\:@F(9LB%:$BU:JPB+<88]<NB0VT]9`)%IIJ,<O
M(UETY_Y+%Y<%C6Y$!MA]%R(NP*26).'3MW(/=Z4[K8\_J""Y`C,2O?EE43-N
MY6=I\5[/.B!7GD*3G]W?-D*>"U5J=PS$4]G0!M8;$X>);SH-OA(,SU:"CH3Y
MWPXN([=A'[RD.&>.A4+@NT.',?)"[$0U8-G1G0ST6$85\VM%[%O_`-8OZNF+
M]*K%HZ3;<-'P[(BFK-L<.:Q%EAH&50%L<)8!!#ZLUZ+T4[TLO)27A+,&37"8
MRF:2$E;H@@!/\53N66JMX9&PD*A6D."],\1A7[B(?L1`[(EN8GJH5MASN-MD
M[S!F"R5AV(LO7QBHA^7@AQ-V.?!0F-M1#N->/7QWFP=T"DE%XIOP3`=O-V+=
M>ZWJ`HS%6GKK<?@/HK^HGW:-LAD->V;K9)TTZP.%8;9W6F17CEY*4LK7LAPL
M-%Z+FI:C(&2$Q('P4O)>14YZ2EG95Z25O%67120IW-J]E/GP,/X=O<>LZ<5$
M89B,&6H5N';)='WI43IN*<L;@A'H_L-TY?1SK?\`T5Z-[[!3#Z.9G^AOA/BP
M5V$<]?!GY&\W3;V3JMF]DHAB,^61K,W-),%,,,NF66'3.ZP!*00I2XR],S]T
ME5=*`*7/+AHJ=,JY:JHE)5T,E?J,K3DN5EPY(UY2[G`"P1<N6O>=,M=0$73B
MGYABGV1\%V;DW<L'^QGX+LW1IV3$O_`^"+MT1+LF:?9"`#+.Z*`*65N2Z92T
MS],Y*W[QRLM*K67!#[I+EYKTRESDN2\E6DK:KIHOQ7(*JH-9R7FK*@N<A/HN
M5IKVM?#Z7\%0\U36BH;Z65I#0*BGIPRKT0!5%*U;*UKJF?)4'BJBJK.2Y+_0
MK<OI;*>G!4HIKAR55T7'12,KJW1"EM5Z*UJ%65EHO1<A15`K665J*JU_<_3O
M>GTP_\0`1A```@$#`00&!0@&"04!`````0(#``01$A,A,5$%(C)!87$0%"-"
MD2`S4F*!DJ&Q%21#<M'P,$!3=8*3P</A-#50<Z)$_]H`"`$!``8_`O\`P@+]
M:1NS&.)\:)5A$ON@5NGK)GKYZM\PI8;@!'.X/[K?)MTNYA$UR^SA!]Y^7R&@
M:_MUE0Z61G"D'EOK_KK;_-7^-8;I*V_S`1\:_5KRWE/)9%/^OR-<TL<2`;R[
M!1^-%#?"5E[H5:3\5K!NS#_[8W0?C0$/2$#$\!J_*OYX>F#UR81>LR"*'ZSG
M@*\,?)E=F[\(.0KJ;V'<>^BA&#C</&ICI[%%^>X`UJQ@<ZZO$;P>1J)V[6,9
M](K1$3L>C2-FP[.V4Y)!YU:70;4VS"2?OKQSZ9S+8Q"6168SH-,@;':SFEL&
M9]'K_JQ;4<M'KQ^5",='12#2,F3+,?'.:_2W0QELFA;VZ12$+I^DM?HGI&3:
MN$U6TY[3CZ+^/HQ\]>R_-0Y[/UWY+3WO3%W-'T8&W1H2BR?50<J$=O80=7WG
M0,Y\23QHI/T?;.&&/FP"/(CA5ITA8!S8>LQEEWYMSJ[S]&K=QOU0QG/^$>F.
M*%B8NC<%2#U-N-^[QJUN<^T"".7P==WR6_>H&-N&_P`<TL\HV;1D9W=NF,<7
M4;M4,]71^SYUEET(.SG=NHX/VU'Z;J[_`&FC9Q#G(^Y<5'?,/UTOZ[.WO%9#
MV?A5UT8QW-[:'S]X>E_W&_*A_>W^Y0\A5[K]Y=*YYU#.B^RM8R9G[M_`>=37
M#=F&-Y/NC-:VWM=W.R5?H0AN[[*M[2)<)#&H^T#>?CZ9+2X&8Y.([QCA44"=
MB%0B\\#T7=Y[RQE8_%V&%IKZ1?U^23](.Q'6T,<Z/A5QT6YW2C;0_O>\/DO@
MXZU9VVGR[JMTUEAIU!NX^=#\J3`WUUI^'N]PHX;(J/T;JZ-Z$:=(K2W<3WK,
M>KNWA:>R-]:[)H3"%U[L:=(I7@?5%!=[,NO!XF;\L4DJ;UD177[1GT2?N-^5
M/(@U.G2998^]R'[(I6ON@[B%&W*YSI^WE1M9KA.CK&V(D]54^TF'/QH6MFF@
M>_)CK2'ZQKI#23\T1NJPU#L[QY_+Z+Z#:=8[5)!<7I)ZO5WA33V?K]J(C%L=
M.KLC3I%++#('CM[O&T7@\+M_S4<\9RDJ*ZGP(^1)X-0R-9[AW4HETP29]CC\
MCX44T:O$</.AZPX$N,QI_P`TPEBPX]X42,8Y5'Z)[N4Z4@C9SGP&X5TCTYTI
M#M1>3ML$?.Z,'B*S^CX__K^-6TUI'L8+A=!5?=D'?4<;-F>S.Q?G@=D^B3]Q
MORH?WO\`[@J6SN$#)+'C..R<;F'C75)6:T?5$=^)[?/`\^K4-[#[X&T3O23O
M!J[MN^2!POGC=5L\@T^K7.QD[M(U8R:212"KJ&&.1&?D2>KRK+LFT/I]UN53
MW4APL$;.<^`W5TETWTG#MEN9BENKYP$!XBO^WQ_%OXU;7%I%L;:==#*O9$@X
M&EA<^ULVV1'?H'9/R)5?<RM\163Q_"MK(2='#EX8JX)?K'?Y4,GVD9QGPK#G
MK#@_A7&HE.XG?7+SJ'H:VG#232+ZUI;<B<F-6,-N4:-8$WJ1O.!GT3M(Z));
M^TB9B,Y'</.M-R^FVO5`=^Y).[-!XW5T89#*0=U2O+(B(L;DLS`=QI;G5[']
M)B37G=HVG'RI7AD21"H(*L#W>%>M6Z?KUF-:<Y$'%*Q.Q6QG;1<QG]E)PU`>
M=++;3QS(XRI5@>--TKT8FHD?K4"\3CWT\:3H?I9]C)%U()9-W^!LT'0AE/99
M3D$>='.X5+96<JSW\JE.JV5A#;LD\ZA9C[2Y)N)6/O%M]+T-:S*9;AU]8*-\
MW'G@2*LH;<J4$*DE2-[,-_HN]HR!H1M8RQ':7E0-Q(%M;Q=G(<[E;W6/VTKQ
M2)(C;PRL""/L]/K$&-N!O'TQ6AXG!SRW5C9O]VB-$F_ZM?-O]VL&*3[M)+<+
MHA!SH/%L<*`&X`8'E21>M36VD[S"<%O"B9!-+(W:D>0EB:26"\N3''V;=W)C
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MV;A]!W]DXQ\CK`'[*["_=%=A?@*["_`5V5^`^1':B)FF<X4=V.=;^5/(>"#4
M?LK:P9TABIU#!W?(W^A+,1.TKG&_ACF/ZSOX<:N+V7+1VXT0H!EB1RQ1EBS@
M'!!XJ:)E]IW,HW\>=*\*:%D&K2!CC6QC#3S8RT:=P^MRK:1GLG2RGBC#NJ0A
M\3:<1COU&K>WOMHD\PZLC]ER>ZOY^-7-V^]+<;*$#B[>%21J&22/M(_$5DX`
M'$T7ZSC.%T\'/T122N-F&75I/</&C!O&D9U=S>52+&CH8COUC&?$5ULLW#"]
MWG49TLRR8ZX[*D^-1)AF$I`$@[.30^-!7/6/!!O;SJ6&*-\1;GD/#/*MW](Y
M7>[^S0>+;JVLG7N[A>JO%M3=P%=8>UF.T<<M6_%):)A8HB)+N3GR6I)$&Y(B
M4^P;JN>DIV&N;6Y8\<#@M37$G_Z92Z+]7NJRLT`ZAVLIY`=QJPM(ADP':R8]
MQ?\`2IYOH)A?$]U&\N,;23,V_P#9J=]7G2&,"XD(CSQTCO\`*C8J=$$(UW+Y
MQGZGE4-M%I2QLCJ9O==^X"FU`;/3D^0%3WC#V$3:(AW;JZJ!2>0I.C[<852)
M+F0?E4/1MOU;6TP9W',=U(@PEE8=4#^TD'YTTQWGA&O-CPHSS':](W:^S'$I
MJX`<@,U@MJGE.UF\&;N_I1&[%"K:D8=QI7FD:XD3<K/P7R'HEN"[2&5M14\*
M*,,JPTD>%")YF:U1M:V_`?XCWBMP"I&OV``=U7?2*R&%S(8XFQGJ#PIFSKGD
M^<E;M-X>`I8G9E175R![VGN/A2R&>180@0VZ[D8"E1!I5=P`I[LRR8?MQ#<#
MYU)+J+!SD1^X*>$G0'&G([AX4L$?87XD^-$9QNJ8JQ:2<G4YX[^53*A8M.3K
MD/:WTYU&4LQ8:^"UL68KOR&'.H4,TFN$@[0[V;'=6E!]I[3>?]3*2`E3N(#N
MOXHPH10)HC&\+J=OQ=B?ZF#_Q``I$`$``@("`0,#!0$!`0`````!`!$A,4%1
M87&!D1"AL2#!T>'P,/%0_]H`"`$!``$_(?\`X@,.!_Y`2P1+!D.F!"RNZ_J5
MG0P$U%>M:BS:IP5BB.C:D@VJKN"]W]6ZQ5^863?.>O`B<]#9K.J^B3!C'Q4:
M5W)#M6W/9/ABI2ZHM/1B5I4;]\%ICL3\?1:P;K$6VD8>=+)B-TY(<`)+([A^
M<"(CT*XKT';!M:IR/:TGT2=4;])3J/SO1(E'%@G=.G]-N0.R/HX)B(R+_`G,
M4FPTXBL0A`Z25='.DX.8ETRTL#Z$I,CIE#A(GM@J]W6(:](J&"X5Z5GT2,5L
MB,20QJR\`YVT"J.X2C?BO:(99H"TKR1J(H54THMO%J4A8#P&;-I2@S*9H+PD
M?,VGG^8',M7C4'@+.,^'22P#M>;NM6)BX/\`&[&Z-M$'$;2GD!:.!5@=%ZD$
MBJ2.EKOZ7P:O<4.MR6-ABJ)*HDK.#8?8)9\?HM/:J385!!.BZJXJ#@&+45T2
MEP/A?I`'A.*;R\.[#$=O,I%G`(*'&;(:_$5'Q6?$VD"$Y]Q',8!GXR#+FA0^
M$C7^G1*'A-DK[3_/[Q/&T2NBD/\`-U+5!4')N,2_D*KJBK(I14)H10?:7!2E
M-XRCP0!,S#&)9YRA\I5$;>8"Y%H>Y859*Z%%^TO`^\055C>5@#NX_P`7VAT'
M:K2OQ0N*8]7<NY3-^F/T$OP[!!V`:;?O$WA5*4X$:<9-)A.>$->K-XG76SQ`
M%?N#\0U[F?Y\PP>L'\CQ*^3?&NSQ>([@H,`Z/#7Q$.6D-:^"E2R`.0A^83]A
M^^-0/'H2>9AW9!%?@1>4SE``L\7K!1I2PXJ_LQ1(YN#54Y)Q/'S16\\_'TS*
M?$HENJOCT]93JM<Q6O[3"(&#0T`JL`?$N6.%YK[!!&##=B3]"5V.3QXF;-UO
M^7<MAD#@G7D0"W#5V$+R#IA[813J0Q76O68*)%G1_J6EI8:AS+&*%1R<K!@D
M,0A52<0'#'FKB"]:TK5+W+$J;?"K]"&O^S.QC'\YB_M8.F/<%?)N@RI9?T.O
MU2KYPK1$8AK,P7A3UW[HVQTCLV`\1N3>KL01]X/M%K,Y\46WJCF;A,KL';>\
M3CL;FY^20EN5\\7".IA#+G/#)"%3W<6.G4KY77_,3J%L=?7K_CX,1<$>`Z=3
M4(65VX".+HI;RT0;8T%J>C-U/5O#RS`[5J_+B#+2Q\.8M&SFVHE[;(3;T'UF
M6B.@C:<W%/)Y_:8M"Y>4<PX,QK@8?0N43D?59''A@3FE`&+/,QYN"C(/:*AC
M97*-C:&HEU!66;O$77<38;;@!!'28OBP:</K,GP\;AD2Y+,N]#0NB)5PR?6`
MAT(M$P#:T'=LPFHL`N7%+U*'KT-ILKZLHI8'3`5L<W''\2!"[.;E*2O0?SZ0
M2Z5U&+\I^(3%ZL&T3J**YKG:I6_K;!%9C'D.XG3^5-PXG!.[M?\`Y$-4.Q<1
M.!QA7&Y"G&7/F>H'X3[(`90'1P2W`6+F>2)$<W(&VJP=7(&UQ9E*H&Q/=R1I
ML&%?HVTB\:5W?X)6!>#G63Q'E?L,<!\,$"17)CV[@KMA\-,6'P-F35.[[A:%
MO<N!JY:*M[8N]HY<`5YJ%1D7GJ?!ROF"=9@DM*N"%U3\;HZF:52SDSES<&)!
M>H2K!(<Y@0WE8WD.!QXL\3\K`\MYCC8/,/&!58"5=G/9U$_)+.*'LQT_7X5/
MNK!@?^3[2O\`S?:?PW]4+<%_KJ4A0ZT<0.8X?!N"!VC%G8ZC<:-+//)[2ZF[
M1NA;44U;2+,,#/V^EI3LQX876EQXS68!LMA5_1*K+LS,5^K'ZM?\T6=![*S+
M@T:%93`)#X'A.X"3IEP85%X\TB]9.X':[#:7*U'($=!2H3I^S8!/F(*LA>D'
M58AC'1GJN8T/V]DW3UBD>X7DBHH]LT!S$3@F#P!)@`A8;BRW<V=[[,!P>;B,
M+%@'C!!S?)Y'E:($RT]*8?"Y75Q'$HOES+,MF!X'7O+F-[I'@:)T4&/\V#G+
M58XK_G2F6O2-=/+7_HC(\PY8.&=66PYN.J/!3L&$Q6OS$B515ACL>(6N=/8L
MJ7MXA5)=F*LVKS<12JVU=G@Q,22)IAJTZ$V@M"]I0)CB.;@3C?,=1A$4G^Y4
MK0?G',#]T-`1A4(`BIJ.#,/:B!?2'&5JQV$1.R4BZ[J5A;<Q6;OI"O"Z:T6G
MMJ%/JUX*1AY7"PH.M@%](7A8`'$X$496"5>1;T&:_P":?:`Q!P9IKF$D;@7X
MQGF]F)=N\._DY"7G6IXN50>D4-=Y1=A]BF5:^@HOP#T)B`VDR&W&)D,V\KP/
MPQ(0P\EG["+I4ATBP](',(-0!Q`\AR7V;9!+;$:Z<<I+<;?M_H0AZ'?N'RG9
M!`]2_P"D?CY.*CIR<EM^?%Q[M;06]=^964TV(.IE<2=#MX(1055O:!5K_J@X
M^E5*)4J%G?($>+`^987KL1VV#W91\2B42I1*-2CXFOI1U*/C4H^)1\0!_G](
M_]H`#`,!``(0`Q```!``````````````````!8W98"*2/;B<8L:2@`2U@!8&
M.#"2X;*("L``S*!'!S,Z9V&4/$%0`0UW1J]TB39M"`!)+`#-4D:()URN[$@!
M0>0@2TQ;C:1MY13V]S92\!ZHLM8^R:1?9A>I'8@8Y5]+8*`1K`!(2!00`8""
M07S.*FF$31R>,`````U,-:*27;VY])`````"YZ!"648(@!:0`````"1RC$":
M.1`"0`#_Q``G$`$!``("`@("`@,``P`````!$0`A,4%187&!D:$@P1`PL5#1
MX?_:``@!`0`!/Q#_`,(U1+PNFD>7'TFA)N8FT/&,F@VF+>)TR3+P)RO"(>,5
M.BW&@/K+@(J15NTX>\BL<\.E(B<(E`@@=WA^)G'J?6'XFO'&,<+@<#-LUSZ`
MJ.Q0QVB$X$XH^F'_`#-Z%-'M;+\!CH:\2G`$>+FA9@JP#RWPP@L(0@:VJ/MS
M>-@"MZYI]3`1S$L:G8^,'5UY^LNXJ-:!.!Q<VAR[()#P;Q3--(I%F)Z7!;!I
MM3DG#[PJ2F3]$VS-%QX2(+P2@ZY,_1^.,@R`6QT.9,8YC6S0%[4+[P72`^P"
MGI,_K^'E\&H%^XR)`:TMCB^'&,[0@1VSLUC%0CM=M/PS-\!'"M*#IR:+0.YS
M3FX*RZ*J$4]?.([W)DP5/$QR-KIO7']9S(<!9@70C1DE5?`#A474)*A:0DYP
M76D@/<-FISB'AXG&N/6-*-FCEKDF!B;5MKE*0-S)#\IZ$&Z@OK%W!J(F@(VO
M<N#3XK-AKAZ$+Q^!@'\LYF(MK$$H:PDB:-^7"X<"V`@/)&,LSA?'8.UR1!3#
M6N`"@%87EXP"H\.Z"`-T]8)*H,@,G:\+J&#3XN*B'R>,&A-?.N/6;#83PI#:
M+U\XCHF2!9V@G6-50(*8@=J/MPH@BJ)=D_AJ*<P1"B^/6.SL1GWGDWBEV$`C
M0>\BH([":T.W-I3.X@:WY76!;1:!^0=D.,.`0NN`NZ>#!VD(#<]GC"D<!Y='
M&_.`G5[%E'&O&%N0+!TNP-Z\85:VQ45>0?/G%\@;P+X!=06&;%DVZQ>-X5*[
M\-:Z$P]?'T=<Q""%IIW,S4`)H7<`77G%T.;>JUWIT8SD'`5ZZ%)HQT$QHEX]
M5`/O#::X%BQ='DPC[GA0(CE1P#DD;FN/>(0%*^-OK&Q&)('1@FG%1;>$',^@
M;]86VNKT/7ZQSP/XY(TAV'C+JBWO6)%+/9BAR'/B174FGK*N!132&;.W^!N'
M2PJ`*GJ8@=C8<$U-KA!#N$E)!%WB"#$-I4%9P.!8)#!?$^!G&.;[848V/;$7
M;361.03DPI^J[4.`8/`)RCT]_&-2*Z$XK53UFXK.>?S@`1P3,=*D)W)X=>BE
M.I'A8WER'<LX:Z`94-1AKB>LLWJ`'`UFZ#60\O8P!\XI%DI9'PL:L,-9`2,!
M"V('F;>LH_9:8DB[2E(9LF+"#0<D1WA#R9M#5'?*8TB^":Z''QDA+Q_7K$B"
M$^M&*12O8TZXLR0A!XLJ3<QX"7H;'?ID/NJX"VA9*QNL;'*HLHS%.#F+`V-?
M\C-'`N4)!K5W_`F4O;D`:KO+X\"0*2`\I[PI3`Y'QN?08W`AG#=&_%/^X(_E
M*LX8Q5A+C,5X4=%.CZN$ZA-5-U#OAK*5(HH&Z&OQZP7(4B<2>,F?42WET(8H
M$3Q68B6!'LQ05=`/9ZR#T`D4K2NTY7`HBL+WKE%M^C-&JCJS@<"95HZ01)57
M&6N-@[0/K*@/.6A2ST2/YS<H6H`4&#I-[QWAJ8<-^,J4-8_"$A:30]D/O!5M
M,4A,472ZPEBK@4`Q(.,JR5R'K)]*#/C(-H$10`M+H`'-%X?[D!I-:/&!^N$!
M15>41B3L2J14"#AF\BHUJ@]E\/G'S%X)*$:2*YR$&XN2-BV5]8"@?+P??^=`
M7HA#13UW@J]LG#S.J3-D7=T#X"95A.U.K?1T8NSO*#P]H+^L-8'$8SRCPX&I
MNBG,HG3O';20[*-=:F%HCK!#A:Z'(1H'*1;%FQU<?*@//O=I4?C$UT*">5.G
MK!]`$D^[K(`#Q@)R(L$^Q>V&)^0-!+>0Q$[V=)AE@T&\&L6L`V'>@FO1@LA_
M[D*;B:YP?TX/!/+J4MXG6*WL@I[.(;)HP\E)UD1T[$`ZP[*XXX4)H;6%I[Q=
M@>%6E9`L)SL[Q12B2.O.-M"@O-*P#W@VBQ2$B[2!U/Q;K:>K#W!]65-EAH*`
M2,'IQ$WETJJ^Z^,@%+0;!OEX9&OYR-3*\`#!'TZ<[I!2KK1FJW+4*4!0FN?7
M^787%DAH;RT."J1+>FPG6LU<08'3C7AC1=#TO"OKQ@#2<PZ=IT8.L%DTZ7MF
MY#?1M$CNM,P'#A@(#X(!BHKSK45B8/>%Y4!2N^KK.*-Y:0)-:FNL4LB-T;-'
MDR]%.-+H].-8"(L\H'`>P[F%Z&::D+"'6NL'0HA.49IK3/0'OT13\F..0++8
M;!J3+)8)V!)Z#76.BF5H70WM==XF;*$Q"""DDQPG2J;(4\J&[S<Z3D*A=4.[
MA@S@#EV`Y&M8N^%65Y8[[7&*R(ZQ3&Q+SD!/UJ+(D.<<!%>=R6J[W,)D8&N#
M0A&M8A6ME$B`D>!AJ"%<+!#Z)A`"B%$P"<'>3APNWH3J*5/\C/82BC#BX+P#
M(^/%%,6YS1R<<8Z0&R6G?TF2W6:Z0<?E@!4!FJ??8R5LB0`!QKC09Q)J$V2!
MU^<0NP(!)MT3"MIHJD?$&\0\BG0(H>EK)$HKM2`Y8."LD)MG0&J<X:/VZD_Y
MA\GK%`*FA"![\X>``\'_`%]Y4B$6`B>,`+-D6VVR&`("04="FR>L%!)'9=2?
M."'C0?4S4W(?C)T0G7$#./&N.N,X\?6G6:>#\$F:/!/IUQAUL)J>)A#QK^L(
M7@?6$-!/C6!Z'ZDX_A`SCZR?K^L0^/UQO$.$)Q^.,@?1/HSCZ\=8D\%UQ)I7
MQ#-**/%1Q0$Y<A6VL!R38(GUG%A,"8`1#DTX'GZD)H,.?K&RE##Z[:2P8Y:P
M-%T99X1/K%)E'M&?NQPE*\YLG`4'EBYUT,,,4%ZR\2VR:UQJ!+,6KY%$:)A!
MUR8XZ<MPTM`(8$[`ZM%9%76GK!L`QTS@H!,K<=):`BNB$N2W)#%@$:>L?522
M;<Z1NQQ!"47<A6EY(]8W'B`&@L@0:>L("5(*!:F_ICJ!4Z':[LB[,?E5U@7B
M2PF(O8PL0<:>_P#5Q]8F50^I#SD]C`._,'U@E#!"CVC*`.LE,1E4>@B/O$J8
MP/?EYH:UDZK"=%D>"#A<"_0YMR@`\8&!Y>&2^(#C!H#(8>/8<XXT-4ZQS"!&
M8X@4;#;KRK^L'^,0U@X!CSEQSNP0!`$<?>3]J%0Y!VIZ.,)+`$ZKMI-N\5HY
M0-5=0!A?(A]\4Z44YP@TES?`8.,HW80T:.W20F3*I>'\J8+E[QH^%39GP&\X
M9@@9`HGA3-[@!X.4LU8;3UCE/5EH"'"#6`1U">]?ZVU./:2=W.7D@SQ;V!KU
MA9X[8A!=8NS%=[!"22D'ZRH+MD-H4?6?&!\)V`M]0%]8+ZP:W-'0]C#9:QU$
M`UH,6+<*54M/_9G%L9ZVZNPZ#,0^I`%T)5W@[UM5P")N*3"@=`X-!D1R((:V
M7TR9L97$!K:G07!M\#DAI'43.[FJ5-4=G+THETV((^2YOSI\5`;$5KXQ')^.
MR@6X%#UC<<4*TH;$OZ9`/Z==TBG&*&(F\2">,D,D'U0`)V^N,GU/J3_8)1H1
MFR)QQ,@:A#^L!H`!^L`;(A.R'Q@#J?K`"PYY[XQ-_P#AFF!IX&<&RP-J,[>W
M`IKTNY]N>J;'LXXSU'-WN)Q!X^L@NN>?K`IK@FU=>Z[^\7--#9LD^'%(37`\
M3C`.!/\`YB'CC]3-UBGZF;AF]-G7U<=&O3D"^C.#7IU)\93A*W:HG$%U]3(#
M9N3Z/X#_Q``I$`$``00"`0,$`P$!`0`````!$0`A,4%187&!D<$0H;'P(-'A
M,/%0_]H`"`$#``$_$/\`XD\X"Z_%)$NEUNGJE</A?C^ZD!BWQU0PAA%I6\U&
M(BB+MNV^M4\;4H`QQZT#,V"T;DKX^A!XJ0M"NBH@XC58\5CTJ(C:X\4=8*;'
M6W)Z9JQ=;"?NJ-ZC!]`[BO2(HE.AW0"Y9J3TI."#)U[ZJUS6JQZ4?C%"!TUU
M6#-8_@D3.#Y-0A2$#98;';S3+F%9Z/GFF#MFK4L)3F['`%7'@1(7Z8XH\IBD
M(2"EC\9#4[^]0PH]HH0/&J;)=D[I0NN-3Z<%8.*9B#I.RAF!$%NW;W%3&%"%
MZ[K,C*VEO]U4`YD<-H_RBUMF*'L+?U0+`66'KNE6=K9C'50@!MO'_M,N"@$3
M8K1@+QXQ11;4=\5INLPO7/@K`N/BL1K^"+P`$=_'B@F^!!$S67S5D2H'`[^*
M8>6,/DZJ2.`/'%!+7QEX#P%3QBECMT'5!MK!`$0MVD"*+2?8I,`CGHJ6S;0U
M60!S]R/%75C@6XJ'>JQT41$7<"`.#BB"+3&NJ0(QP[(XJ$66`)U''FB+18R/
M.WJAPE>%(QR[XJ`K[/Z.JC&;=TMTD6U:@@2KV?:M$8:S>8%!C:LS`6C$5`%'
M$<":HMH8P,QU_"(L4;Q`7N1S4I>"#=/!U0-6Q8#L_%*K(%$[U1<KCI(J#NQD
MQ>VYU21D6D<&O4J<\J,C4KU%=8IAZ`?W6$0\+5-UE@!M6U$H%_HK#T401:Y0
MP$60UQ,X]*;%A!NA@PME#>NQ%`$6'%_>A-H+3[<T0`]%EY.HJQ'7TBBQ%.C$
M8J(,R&*O!9E^[4$@,ZHF"LED<SUU200N''\"22<`CW?Q0J!MXPCCBIMS2;C^
MJ">28+HTJ6E:-D8Q0:"&`:/Q%0`PA8Q^&HI(NXQ,ZJ(LPT$V"[,/B@8F#)$[
M]]5F719FWK4(@2$`=^N*%@DE8GBHMB&BK$0PGM:I2S%<Y\TDEP>JD2727.18
M"@0R#%_%0$O;FDKK;$QZCYK@"8LQBL,4L1JK'@SU5R'!H/\``J85V6FF`F=Q
MF_BH(0P@Z9M0`O+IQK5J'41&OJ`L"P^_BD4.\S?NEC@RY'+5UGLVC&4H%$9B
M.!,B5`H9?1CTFD4P'HM^:5V1A!:.N*PVP8?\K!(!6[9[CQ6@22S5R(M%X^U0
M;QUF*D$N%:<Q\Q6-80BN4<*9%(XU#1W6C3"\5$PFQF3K!4PE%T#/VZI+.!AJ
M"29N6:1S-;'@1CTHD<AOS\4>QT]J`M,<G+Q%,R!$+05.B)8G\J3)DQ5Y=0%N
M(M0K$V;ZH&4&P9'^5"9,$3X^JE`DEZX>JFK`0-K,O%*ZJ!8&-%3S86"Q0+,3
MP((W4[[4D+G#=2"GP_+Q2N]=LQ1!'#,XK,6LI*QON.]/446+^:A%QA$:N5*=
M!A,!Q%!&+/GFB$F%W\:KB7!)AH0S<,1OFB!8M.=>U0#-@B=/-"'8WG[1Q0Q;
MB8ZJ!6+I$_O%0-Y1C/\`E"`.,_%!X%(.OZJQ!$E!&.HH860I9O[<5)P#`W3U
MH5&+DD]4Q`9PO,1''%2-V>M:H7%P:X^H%T:H2Q>@:Q$1V;^:@BQY-!?BEJQ8
M`U+0JE?!_NLHQ!Q46B)>-E0$0K$RZ(JP?AW&YJ%L9I$#1P_Y0?;?[Q4=14D0
M9*@+%8_$5"Q;KQ2IXBR'%8S^_P#E8]*C5!&+11QQ1]BK$6\41[5CJ*+'%%L6
MK'I1;J/X?%8K'45BL=5\5\49M89\4Q<69"T19F>*26DU&?6I;Q%Q&M>E+8.L
M%*(`APXJ$('.?ZH@&(8%,EE</!^(J/<R>:AF4!A,>&ESALI$$3C%0.`W7Q0W
M4*X.NZ#T8G1223KPA-%%H+#@S//52WA`(1GQ4&65XR.).J)9;9OC'6DHL@U8
M[Y&M=%@HMG&?^./3Z#TM4AT#S^Q4`L*QU^Q5B`)#.;_%$!,:Q\ZHMA/Z_%"!
M)89=>/:K$CL\^:B`RI%NN5IL@:)X'6JCB9QXJ"T0&N$LQ1(2T#8/FKEERWZI
M`I*>,30L$/RIN9`D6-1B],IP8>6B26&P,>](81HG?BB!&&B6)Y'52X'/YM4$
MSE,!\QJB)`@-<>*B.H_Y@3=@,4P@%F_FH.0+`T$'D_<4P`+1D[YKJ.FL<4>H
M<?:U$P$6XW3!F94"9MWQ1$V+/BIMTQXH,"7L]JM^7%"6"6#OGR46@6C/DH;L
M6%AZ^*,",9>:/84*,E^>*,VRQU4HN6<^3=#!R1#XHN8(0OSZ40==?]<=5CJ/
MI`/BIQUBIUB*.%JQ/>?W7I0!;BN#T5$5CTK<[J(]*&,6^D?:A@@L<5BN-:4E
M/XK'I_#_Q``I$`$``@("`0,#!0$!`0`````!`!$A,4%187&!P9&Q\!`@H='A
M,/%0_]H`"`$"``$_$/\`XF/9>B\/*KZBT-]O#.C#B-+)0%_+B#+%,5E\&)6J
M=BGWQ*&U+%9#=8A""!4'\'K,Y3#IXKB:_37H0P9JVB!OAZ\37M'%8EA.VI<S
M37"68<P*/$+K6M_H'M#6!*<1077L@A=X3C\Z@<&$_"8*<]=0^TUH]"6`PXS,
M6A&O;]BMJ3+070>.H6(@)L:7Y8F$;+:F"H5?A,(B#?5$P[4C59-ODHE;VX$&
ML;]NH;LL@[7EN+F5@K*NWS#1!CVE65<6#(++R/<SNZ7-D*GCJ50W5W0_E05L
M@3E=5W-@<.OF)MOC7#4$K%O+'M!.,/4H`U0XYJ6%&.9Z<0*UBHNO8A1;4<_'
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M-2Z0J<$^FI0_1@Z:O&N^(=95>H9W#'B`:<''MTRPHML="N8"-WCJ:B@XI_-S
M0'/4Q])5/IQ+"J@(&KIZ#V^D&D-.OM"P`,(9K&26'$<-S58J:FO:&/'Z&/0X
MBJQRT5N61W%&6APOV)_!^P.WM;NL8^TLF8*\!0V+P0W7$2G#JDE"(5$71:NP
M5S,38N05V'+34Z&D0?Q;-Q#W9C=7A(RN*`^MEUS"P@:?`)@[,*Z]*[EYYA0%
M<+1YY?$W5X*_V7FNH)6,5$4,-'IU#%7S6/O$'(+3T'=1M4-]CO\`J6$MXX[@
MKBE:.WKQ4%%BG7H?:?$^(>/:([8"%87`O@PL7\3>0O,#BGLX]NY6PJ"[UZ0V
MFOU:\3*J5BO%R_%P,)]_$O1\-\<(YIC.%EK4:#.JCLCPML;AOA=10UE#,UZ^
M(+?8J92]8C7%*./!7FX%'3U_LJD';1S%896^8)Z<3&&`^_4NX%MY>)2'1`%(
M;((P4%Y=UQ$0,56V6*[(K&4WZ#S+`%W;?^P;*,&GTX8)HX'IXFO%2O\`R8^)
M-0J&U:?J_P`FFM8_&513JLPIX4SQ[3:-TZ>/2O$UQ7ZA0%;M035=2HR2CL&@
M3N=\^IH>>O,#..2GFS"BZ!%"7B`B`%DL^79#J*%F>R/)!Q%`JK_R<E\'-RA;
MZP4P6[MK"I5>TU=YO4`UL:5B%++P<2M'@(46TRD*V=13`;&7'\1*55G3*J@:
MJ;>"L\Q6D\F?ZCRU1J#J"G(_V1$[;O%^GI4M#O1>C'B5KAY_.(8#`='F%9V)
MG\XE-"^AZ>>XFEX:!B:HO7ZHFKN-?2;F^;3?E2V*IH4=<),`?0-0D%K5MQ]D
M64[%T>ND"H,'B4:A0,JCN:LK6<=RP9L-8.((-<.9=<1IMY@5S-<2RMV\)=8Z
MA*<O'\0`%:-7Q!..)J'I5<2RCB:QJIJNYKQ7$/1])?M4U7<...ID/2:]OV54
MU[37B5_$U[3XGQ*N@X:89SF&@XF"IR+JL>[,%;!I$1HU68LO^#*R=<$6G15L
MLNF:^)6&M(BJ#')W$*NB12:`Z3`B%TM>8%KLJ#BR<.H:$PE8*4+KD@]@Y"LU
MJ*BE.-!]H`5]#Q"ARZ(46A0Z:K^YQ_RUXJ:]H"VIAUBJ[E`(4ZT1V%2M?$JF
MR:#16H!Q;+*ZE=%/B(*!2L,5JLJ0/0K?),`W1$2`ZV<#Z2PC0:/SB''-<U9`
M.:R;K8\'I$O#@X"(&-&BN*W&KRJM)U`0M;^SXB*X+@.P^9F-':\/]0K0P;]H
M_2M'[2G!.P2LG%?\W55<'(;"JK[12"`\,:UB)LV:BD:JM!K7GN9'*!#NOSX@
M"'31Z?:7HB#6<8AA(OOQ+\J!5;_B4%#R[^O$`,&"`=BG/^05*)?7D@X6YW4"
MJ;K4**QC"838X[/ZEY&U`K<OIH./,+%7.[](H6MM>A_L5\\37M_T^/T^(AUJ
M!7BI\0PB8=(M[A@HP$,:E5XJ57B48XX2O:HA])KVGQ*+OF:QU*J:]I\37BOV
#?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
